CN106727964A - Composition of dibenzopyrans ketone and morphinane alkaloid and application thereof - Google Patents
Composition of dibenzopyrans ketone and morphinane alkaloid and application thereof Download PDFInfo
- Publication number
- CN106727964A CN106727964A CN201611174510.6A CN201611174510A CN106727964A CN 106727964 A CN106727964 A CN 106727964A CN 201611174510 A CN201611174510 A CN 201611174510A CN 106727964 A CN106727964 A CN 106727964A
- Authority
- CN
- China
- Prior art keywords
- composition
- mangiferin
- rotundin
- present
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 150000002576 ketones Chemical class 0.000 title abstract description 5
- 150000003810 morphinanes Chemical class 0.000 title abstract description 4
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 claims abstract description 59
- 239000003814 drug Substances 0.000 claims abstract description 37
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229940043357 mangiferin Drugs 0.000 claims abstract description 30
- UELPQYXGRIZTHA-UHFFFAOYSA-N Rotundin Natural products CC=C(C)/C(=O)OC1CC2(COC(=O)C)OC2CC(O)C(=C/C3OC(=O)C(=C)C13)C UELPQYXGRIZTHA-UHFFFAOYSA-N 0.000 claims abstract description 26
- UELPQYXGRIZTHA-XSEBJXQCSA-N rotundin Chemical compound C1[C@H](O)\C(C)=C/[C@H]2OC(=O)C(=C)[C@@H]2[C@H](OC(=O)C(\C)=C/C)C[C@@]2(COC(C)=O)O[C@@H]21 UELPQYXGRIZTHA-XSEBJXQCSA-N 0.000 claims abstract description 26
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims abstract description 12
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims abstract description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 239000008280 blood Substances 0.000 abstract description 27
- 210000004369 blood Anatomy 0.000 abstract description 27
- 235000000346 sugar Nutrition 0.000 abstract description 23
- 238000011161 development Methods 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 240000007228 Mangifera indica Species 0.000 description 26
- 235000014826 Mangifera indica Nutrition 0.000 description 26
- 235000004936 Bromus mango Nutrition 0.000 description 25
- 235000009184 Spondias indica Nutrition 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 23
- 239000000463 material Substances 0.000 description 20
- 241000029486 Stephania sinica Species 0.000 description 19
- 239000000284 extract Substances 0.000 description 17
- 230000009471 action Effects 0.000 description 13
- 230000000144 pharmacologic effect Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- -1 Novo Nordisk) Chemical compound 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000522254 Cassia Species 0.000 description 5
- 235000002722 Dioscorea batatas Nutrition 0.000 description 5
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 5
- 240000001811 Dioscorea oppositifolia Species 0.000 description 5
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 244000301850 Cupressus sempervirens Species 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- 241000218989 Trichosanthes Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000000022 bacteriostatic agent Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- CAXNYFPECZCGFK-UHFFFAOYSA-N 2-phenyl-2-pyridin-2-ylacetonitrile Chemical compound C=1C=CC=NC=1C(C#N)C1=CC=CC=C1 CAXNYFPECZCGFK-UHFFFAOYSA-N 0.000 description 2
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 235000003717 Boswellia sacra Nutrition 0.000 description 2
- 235000012035 Boswellia serrata Nutrition 0.000 description 2
- 240000007551 Boswellia serrata Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 2
- 240000008620 Fagopyrum esculentum Species 0.000 description 2
- 235000014693 Fagopyrum tataricum Nutrition 0.000 description 2
- 244000130270 Fagopyrum tataricum Species 0.000 description 2
- 239000004863 Frankincense Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 241000772413 Lutrogale perspicillata Species 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- 241000508269 Psidium Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010062198 microangiopathy Diseases 0.000 description 2
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000131329 Carabidae Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 235000008375 Decussocarpus nagi Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000009451 Hyperglycemic Hyperosmolar Nonketotic Coma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 239000004425 Makrolon Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 235000014631 Myrica rubra Nutrition 0.000 description 1
- 244000132436 Myrica rubra Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 241001116757 Pyrrosia lingua Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 244000173853 Sanguisorba officinalis Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000000485 Smilax china Nutrition 0.000 description 1
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 1
- 240000009022 Smilax rotundifolia Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 240000004824 Trimezia steyermarkii Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000009136 dragon's blood Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000021393 food security Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229930193981 timosaponin Natural products 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008782 xin-kang Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The composition of a kind of dibenzopyrans ketone and morphinane alkaloid, with mangiferin and rotundin as active component, the compatibility relationship of two kinds of compositions by weight is：Mangiferin 10%~90%, rotundin 10%~90%.Animal experiments prove that, the present composition can improve blood sugar and glycosylated hemoglobin, the DEVELOPMENT PROSPECT with medicine.
Description
Technical field
The present invention relates to a kind of composition for taking from plant, more particularly to a kind of dibenzopyrans ketone and morphinane alkaloid
Compatible composition, and the application of its extract and active component in prevention and treatment diabetic composition is produced.
Background technology
Diabetes (Diabetes Mellitus, DM) be it is a kind of because internal insulin is absolute or relative deficiency caused by
A series of clinical syndromes.The disease can also cause some complication in development process, such as：Hypoglycemia
(Hypoglycemia), DKA (Ketoacidosis), non-ketone hyperosmolar coma (Nonketotic
Hyperosmolar Coma), angiocardiopathy, chronic renal failure, PVR, DPN and microangiopathies etc..Sugar
The conventional medicine of urine disease treatment mainly has three major types：Biological medicament class, such as：Insulin (Insulin)；Chemical drugs, such as：Sulfonylurea
(Sulfonylurea), biguanides (Biguanide), glitazone (Glitazone) and Chinese patent drug class.It is limited to not have still at present
More ripe insulin non-injection administration technology, it is used still based on injection, and injection process there is also security risks.
Though chemical classes medicine is with stronger hypoglycemic effect, big to toxic and side effects such as liver, kidneys, it is also easy to cause cardiovascular complication
Aggravate.Additionally, also have some medicines, such as：GLUCAGON LIKE PEPTIDE (Glucagon-like peptide 1, GLP-1), fat
Be acylated GLUCAGON LIKE PEPTIDE (NN2211, Novo Nordisk), Exendin-4 () and poly- second two Amylin
Exendin-4 (Chinese invention patent application 00809516.7) of alcohol modification etc., though blood sugar, drop can be effectively controlled after long term administration
Low-saccharification Hb H bA1c numerical value and improvement β islet cell functions, but because the also same purpose of these molecules is in nervous centralis
Acceptor, so the symptom of vomiting and dizziness is more difficult after administration avoid, and administering mode is still based on injection.Another kind of DPPIV enzymes
Inhibitor, though can be oral, it will produce inhibitory action to the big fermentoid in organism, so as to can be distributed body fat
Change, and the actual effect of administration is also relatively poor.
Chinese invention patent application 93100485.3 discloses a kind of health buckwheat foodstuff, auxiliary with tartary buckwheat powder as base-material
With soyabean protein powder, then the Chinese herbal medicine natural component such as matrimony vine, ginseng, the wind-weed, calcium activated is added, its formulation weight percentage composition
For：Duck wheat flour 60-80%, soyabean protein powder 15-30%, LBP-X 0.5-2.5%, timosaponin 0.2-0.5%, people
Gracilis polysaccharide 0.5-1.5%, calcium activated 1.2-4.3%.The food of composition has therapeutic action to diabetes.The health food is with buckwheat
Based on wheat, the diet of diabetic can be played a role, but effect in terms for the treatment of needs further experiment card
It is real.
Chinese invention patent ZL95116521.6 discloses a kind of tonic hypoglycemic capsule and preparation method thereof, using cultivated land,
The taste bulk drug of the Radix Astragali, the fruit of Chinese wolfberry, the red sage root, golden cypress, the wind-weed and Chinese cassia tree etc. 20, through special processing and processing.The Jiangtang capsule
It is made after being crushed by Chinese medicine, because the content of cellulose for containing is more, and sugared absorption can be slowed down, adds monkshood and the medicine of Chinese cassia tree two
Cause that medicine hypoglycemic effect is more notable after material, be the emphasis place of the invention.
Chinese invention patent application 99126988.8 discloses a kind of capsule for lowering sugar of diabetes, with the dried rhizome of rehmannia, root of Chinese trichosanthes,
The medicinal materials such as radix scrophulariae, the wind-weed, golden cypress, the coptis, pilose antler, Bian Gui, Chinese yam, gypsum and dry lotus root starch are key component, are treated by diabetes
Disappear on causing, in disappear, under disappear and the food illness such as diuresis more.
Chinese invention patent application 02107203.5 discloses a kind of Chinese traditional compound medicine for treating diabetes B, with Pueraria lobota
Root, root of Chinese trichosanthes, rhizoma atractylodis, radix scrophulariae, the raw Radix Astragali, Chinese yam, gypsum, Chinese cassia tree, RADIX ACONITILATERALIS PREPARATA, Ramulus euonymi, ground beetle, Ramulus Taxilli, silk cocoon,
The natural traditional Chinese medicines such as stir-baked SQUAMA MANITIS, leech, dragon's blood, chinaroot greenbrier, the wind-weed, gynostemma pentaphylla, the dried rhizome of rehmannia, the tuber of dwarf lilyturf, the radix paeoniae rubrathe, the root bark of Chinese wolf-berry, rhubarb are
Raw material, is made up, for the treatment of type ii diabetes and its complication of operations such as crushing, decoction, drying, sterilizings.
Chinese invention patent application 200310110332.7 disclose it is a kind of treat diabetes medicine ginseng stilbene Chinese yam cream and
Its preparation method, by " monarch " medicine：Chinese yam and ginseng；" minister " medicine：Sea otter, hippocampus, asafoetide, frankincense, myrrh, safflower, Chinese cassia tree, treasure
Pearl, muscone, root of Chinese trichosanthes, golden cypress, the Radix Astragali, mango leaf and Guava Leaf；And " making " medicine：The common compatibility of the medicinal materials such as borneol and
Into.By broken section of mixing of the medicinal materials such as Chinese yam, ginseng, root of Chinese trichosanthes, golden cypress, the Radix Astragali, mango leaf and Guava Leaf, sesame oil is soaked in
In, through heating after three days, filtering adds red lead in oil strain, then stirs evenly, and receives cream；By in ointment addition cold water, it is stirred continuously,
Water is changed in extruding；Cream slow fire of getting it filled melts, and adds nacreous layer powder, borneol powder, muscone, sea otter, hippocampus, asafoetide, frankincense, does not have
The fine powder of the medicinal materials such as medicine, safflower and Chinese cassia tree, stirs evenly, and is split in and plaster is made on non-woven fabrics.Obtained ointment supplementing qi and nourishing yin, life
Tianjin is quenched the thirst, and has functions that to treat type ii diabetes.
Mango leaf dries leaf for Anacardiaceae Zhi Wu Mango Mangifera indica L.'s.Major function is cured mainly to disappear
Stagnant, dispelling wind cough-relieving, tradition is usually used in treatment indigestion, cough and skin and itches.People not yet recognize it to what prevents
Treat the pharmacological action of diabetes.
Stephania sinica is the dried root of menispermaceous plants stephania sinica Stephania sinica Diels.With heat-clearing
Removing toxic substances, blood stasis removing analgesic effect, for the infection of the upper respiratory tract, sphagitis, stomachache, acute gastroenteritis, bacillary dysentery, malaria, wind
Wet pain, trauma pain etc.；Traumatic injury, venomous snake bite, sore swollen toxin etc. are controlled in external application.People also not yet recognize it to prevention
What treats the pharmacological action of diabetes.
The content of the invention
It is it is an object of the present invention to provide a kind of composition, mango leaf and stephania sinica is compatible, with improvement
The pharmacological action of blood sugar and glycosylated hemoglobin.
It is another object of the present invention to provide a kind of composition, the extract of mango leaf and stephania sinica has to be improved
The pharmacological action of blood sugar and glycosylated hemoglobin.
It is yet a further object of the present invention to provide a kind of composition, it has with mangiferin and rotundin as active component
There is the pharmacological action for improving blood sugar and glycosylated hemoglobin.
A further object of the present invention is to provide a kind of composition, and mango leaf and stephania sinica is compatible, and its is carried
Take thing isoreactivity composition and be made medicine, food and health products, for the prevention and treatment of diabetes.
A further object of the present invention is to provide a kind of composition, its so that mango leaf and stephania sinica is compatible, and
Its extract isoreactivity composition, the also prevention and treatment for diabetes combined with other materials.
" mangiferin " alleged by the present invention, also known as asphonin, chemical name is 2- β-D- glucopyranosyl -1,3,6,7-
TetrahydroxyKetone, is a kind of flavone compound.It is slightly soluble in methyl alcohol, ethanol, water, dissolves in hot dilute methanol, hot Diluted Alcohol, no
It is dissolved in non-polar solven.Can be directly synthesized chemically it is prepared, typically from the plant containing mangiferin or Chinese medicine
(such as：The wind-weed) middle extraction.This kind of medicinal material through solvent, such as：Water, ethanol, methyl alcohol, propyl alcohol, butanol or the pure aqueous solution, high temperature are carried
Take, concentrate after separate etc. step obtain purity more than 60% mangiferin (Chinese invention patent application
200710066354.6).This kind of medicinal material successively through alcohol extracting, decolourize, go solvent, dilute alcohol dissolving and go what the steps such as solvent obtained to carry
Mangiferin purity is more than 90% (Chinese invention patent application 200610079234.5) in taking thing.These contain the medicinal material of mangiferin
Such as：But it is not limited only to, mango leaf, myrica rubra leaf, the wind-weed and pyrrosia lingua etc..
" rotundin " alleged by the present invention is CAS No.：The compound of 10097-84-4, white or yellowish crystallization；
Odorless, it is tasteless；Chance light is heated and easily turn yellow.Dissolved in chloroform, it is slightly molten in ethanol or ether, it is insoluble in water；In dilute sulfuric acid
In it is readily soluble.Fusing point is 141 DEG C~144 DEG C.
Composition alleged by the present invention, also including the various excipient substances being adapted with contained compound or composition, with
The formulation beneficial to administration (drug delivery) is formed with, such as：But be not limited only to aqueous solution injection, powder-injection, pill, dissipate
Agent, tablet, patch, suppository, emulsion, creme, gel, granule, capsule, aerosol, spray, powder spray, sustained release agent
With controlled release agent etc..These pharmaceutic adjuvants both can be it is conventional use of in various preparations, such as：But it is not limited only to isotonic agent, buffering
Liquid, flavouring, excipient, filler, adhesive, disintegrant and lubricant etc.；Can also be to be adapted with the material
And select what is used, such as：Emulsifying agent, solubilizer, bacteriostatic agent, anodyne and antioxidant etc., this kind of auxiliary material can effectively improve combination
The stability and dissolubility of compound contained by thing change rate of release and absorption rate of compound etc., so as to improve variousization
Compound metabolism in vivo, and then strengthen the administering effect of composition.Further, it is also possible to realize specific administration purpose
Or mode, such as：Sustained-release administration, controlled release drug administration and pulsatile administration etc., and the auxiliary material for using, such as：But it is not limited only to gelatin, white egg
In vain, shitosan, polyethers and polyester-based polymer material, such as：But be not limited only to, polyethylene glycol, polyurethane, makrolon and its altogether
Polymers etc..Alleged the main of " being conducive to administration " is presented with：But be not limited only to improve therapeutic effect, improve bioavilability,
Reduce toxic and side effect and improve patient's compliance etc..
In aqueous solution injection, auxiliary material generally comprises isotonic agent and buffer solution, and necessary emulsifying agent is (such as：
Tweeen-80, Pluronic and Poloxamer etc.), solubilizer and bacteriostatic agent etc..Additionally, also including containing pharmaceutically acceptable
Other pharmaceutic adjuvants, such as：Antioxidant, pH adjusting agent and anodyne etc..
Auxiliary material for producing oral liquid generally comprises solvent, and necessary flavouring, bacteriostatic agent, emulsifying agent
With colouring agent etc..
Auxiliary material for producing tablet generally comprises filler (such as：It is starch, Icing Sugar, dextrin, lactose, amylum pregelatinisatum, micro-
Crystalline cellulose, calcium sulfate, calcium monohydrogen phosphate and mannitol etc.), adhesive (such as：Ethanol, starch slurry, sodium carboxymethylcellulose, hydroxypropyl
Base cellulose, methylcellulose, ethyl cellulose, hydroxypropyl methyl cellulose, gelatin solution, sucrose solution and polyvinyl pyrrole
Aqueous solution or alcoholic solution of alkanone etc.), disintegrant (such as：Dried starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, crosslinking
Polyvinylpyrrolidone and Ac-Di-Sol) and lubricant is (such as：Magnesium stearate, superfine silica gel powder, talcum powder, hydrogenation
Vegetable oil, polyethylene glycol 4,000, polyethylene glycol 6,000 and magnesium laurylsulfate etc.) etc..
For produce emulsion auxiliary material generally water, oil (such as：Aliphatic acid), emulsifying agent, and necessary preservative and rectify
Taste agent etc..
Auxiliary material for preparing granular agent is similar with tablet, but granulation process is different.As needed, by obtained granule
Load capsule after mixing with glidant and obtain final product capsule.
" organism ", " animal " or " patient " alleged by the present invention refers to people, wild animal and domestic animal (Livestock).
Wild animal is the animal without domestication under nature.Domestic animal be to provide for food source and artificial feeding it is dynamic
Thing, such as：But it is not limited only to dog, cat, mouse, rat, hamster, pig, rabbit, milk cow, buffalo, bull, sheep, goat, goose and chicken etc..Give
" patient " or " organism " prioritizing selection mammal for the treatment of is given, especially people.
" prevention " alleged by the present invention refer to not by clinical criteria assert disease before, it is various for preventing disease from occurring
Or means or the measure of development, including medical science, method physically or chemically, with prevent and reduce disease various symptoms generation or
Development.
" prevention diabetes " alleged by the present invention refer to refer to the present composition for not meeting " diabetes " clinic also
Target, continuity over time will slowly develop into the potential patient for being clinically defined as " diabetes ", so as to improve these
Tolerance of the patient to glucose, promotes human body to the ability of glycometabolism, increases sensitiveness of the human body to insulin.It is this kind of potential
Patient often suffers from " metabolic syndrome (Metabolic Syndrome) " (Annnu.Rev.Nutri., 2005,25,391-
406；Annnu.Rev.Med., 2005,56,45-62；Nat.Rev.Drug.Disc., 2006,5,295-309；
Nat.Rev.Endocri., 2006,2,335-348), such as：Obesity, insulin resistance, glucose intolerance, hypertension, artery
Hardening card (antherosclerosis), dyslipidemia (dyslipidemia) (triglyceride levels i.e. in blood are higher,
HDL is simultaneously relatively low) etc..
" treatment " alleged by the present invention refers to prevent and reducing the generation or development of disease, make the development of disease course
Or exacerbation is able to suppress, contain, mitigate, improve, slow down, stop, postponing or invert, when described holding and/or medication
The various indexs of disease, disorderly or pathologic state include mitigating or reducing symptom or complication, or cure or eliminate disease
Disease, disorderly or situation.
" treatment diabetes " alleged by the present invention refer to that the present composition is used for into the trouble that clinical diagnosis is " diabetes "
Person, improves tolerance of these patients to glucose, promotes human body to the ability of glycometabolism, increases sensitivity of the human body to insulin
Property.And then cause being controlled in normal level with fasting blood-glucose after the meal for patient.Because the ability to glucose metabolism is obtained
To improve, so as to slow down the various angiocardiopathies, chronic renal failure, PVR, the god that are produced by long term hyperglycemia
Through lesion and the occurrence and development of microangiopathies.
" food " alleged by the present invention refers to that the various compounds of present invention offer, composition or extract are made can
Edible single compound or composition.The production and manufacture of this kind of single compound or composition should meet relevant food peace
Full standard, but these food security standards must not limit the present invention.
" health products " alleged by the present invention refer to various compounds, composition or the extract system that will include present invention offer
Into edible single compound or composition to impose on patient, the purpose prevented and treated to disease is played.It belongs to
Food alleged by the present invention, but its production, manufacture should also meet various related requirements, standards and norms to sale.
" medicine " alleged by the present invention refers to that can be used for preventing or treating the single compound of certain disease, various chemical combination
Composition, Chinese medicine and its extract that thing is formed, or refer to the composition or preparation with single compound as main active
(formulation), also refer to that by multiple compounds be the composition or preparation of active component." medicine " should be interpreted to refer to root
According to the legal provisions of a state, examined by its administrative organization for setting up and grant the product of production, also referred in order to be passed through
During examination ＆ approval and permission production, it is all kinds of physical forms of active component containing single compound to be formed." formation " should
It is interpreted as being obtained by approach such as chemical synthesis, bioconversion or purchases.
A kind of composition that the present invention is provided, mango leaf and stephania sinica is compatible, the two kinds by weight compatibilities of composition
Relation is：0.3 part~7 parts of mango leaf, 0.1~5 part of stephania sinica.So that composition can play improvement blood sugar and saccharification blood
The pharmacological action of Lactoferrin.
Another composition that the present invention is provided, mango leaf and stephania sinica is compatible, and two kinds by weight compositions are matched somebody with somebody
5 relations are：1~3 part of mango leaf, 0.2~2 part of stephania sinica.So that composition can play improvement blood sugar and HbAle
The pharmacological action of albumen.
Another composition that the present invention is provided, mango leaf and stephania sinica is compatible, and two kinds by weight compositions are matched somebody with somebody
5 relations are：1~3 part of mango leaf, 0.5~1 part of stephania sinica.So that composition can play improvement blood sugar and HbAle
The pharmacological action of albumen.
It has also been found that, mango leaf and Radix Stephaniae Japonicae extract also have the pharmacology for improving blood sugar and glycosylated hemoglobin to make
With.
Another composition that the present invention is provided, takes 0.3 part~7 parts of mango leaf by weight, 0.1~5 part of stephania sinica,
Plus 50v/v%~90v/v% alcohol refluxs are extracted 2 times, wherein, the 1st time is 8 times of amount 50v/v%~90v/v% ethanol, 1~3
Hour, the 2nd time is 6 times of amount 50v/v%~90v/v% ethanol, 1~2 hour, after filtration, merges 2 filtrates, and second is recovered under reduced pressure
To without alcohol taste, relative density is 1.20~1.34 to alcohol when continuing to be concentrated under reduced pressure into 50 DEG C ± 5 DEG C, obtains extract.
Another composition that the present invention is provided, takes 1~3 part of mango leaf by weight, 0.2~2 part of stephania sinica, plus
50v/v%~80v/v% alcohol refluxs are extracted 2 times, wherein, the 1st time is 8 times of amount 50v/v%~90v/v% ethanol, and 1~3 is small
When, the 2nd time is 6 times of amount 50v/v%~90v/v% ethanol, 1~2 hour, after filtration, merges 2 filtrates, and ethanol is recovered under reduced pressure
To without alcohol taste, relative density is 1.20~1.34 when continuing to be concentrated under reduced pressure into 50 DEG C ± 5 DEG C, obtains extract.
Another composition that the present invention is provided, takes 1~3 part of mango leaf by weight, 0.5~1 part of stephania sinica, plus
50v/v%~90v/v% alcohol refluxs are extracted 2 times, wherein, the 1st time is 8 times of amount 50v/v%~90v/v% ethanol, and 1~3 is small
When, the 2nd time is 6 times of amount 50v/v%~90v/v% ethanol, 1~2 hour, after filtration, merges 2 filtrates, and ethanol is recovered under reduced pressure
To without alcohol taste, relative density is 1.20~1.34 when continuing to be concentrated under reduced pressure into 50 DEG C ± 5 DEG C, obtains extract.
Further study show that, mangiferin and its pharmaceutically acceptable salt are (such as：Mangiferin sodium salt and mangiferin sylvite)
With rotundin and its pharmaceutically acceptable salt (such as：Rotundin hydrochloride and rotundin sulfate) it is active component, also show
Go out to improve the pharmacological action of blood sugar and glycosylated hemoglobin.
Another composition that the present invention is provided, it is with mangiferin and its pharmaceutically acceptable salt and rotundin and its medicine
Acceptable salt is active component on, and the compatibility relationship of two kinds of compositions by weight is：Mangiferin and its pharmaceutically acceptable
Salt 10%~90%, rotundin and its pharmaceutically acceptable salt 10%~90%.
Another composition that the present invention is provided, it is with mangiferin and its pharmaceutically acceptable salt and rotundin and its medicine
Acceptable salt is active component on, and the compatibility relationship of two kinds of compositions by weight is：Mangiferin and its pharmaceutically acceptable
Salt 51%~90%, rotundin and its pharmaceutically acceptable salt 10%~49%.
Another composition that the present invention is provided, it is with mangiferin and its pharmaceutically acceptable salt and rotundin and its medicine
Acceptable salt is active component on, and the compatibility relationship of two kinds of compositions by weight is：Mangiferin and its pharmaceutically acceptable
Salt 61%~90%, rotundin and its pharmaceutically acceptable salt 10%~39%.
The various compositions that the present invention is provided, with the pharmacological action for improving blood sugar, can be as unique or main
Active component and being applied to produces medicines, food and the health products of various prevention and treatment diabetes, or a kind of or many with other
Planting, there is the chemical substance or medicine that improve diabetes to give organism in the lump.These chemical substances are such as：But it is not limited only to mango
Leaf extract, Radix Stephaniae Japonicae extract, mangiferin and rotundin etc..Alleged " giving organism in the lump " refers to that the present invention is various
Compound has individually or with other one or more and improves after the compound of diabetes, extract or medicine mix through single
Method of administration, such as：But it is not limited only to, oral (Oral), nasal cavity (Nasal), (face) cheek (Buccal), transdermal
(Transdermal), lung (Pulmonal), vagina (Vaginal), subcutaneous (Subcutaneous) or vein
(Intravenous) organism is given；Or with other one or more there is the chemical substance or medicine that improve diabetes to distinguish
Organism is given through various methods of administration.
A kind of pharmaceutical composition that the present invention is provided, is active component with the composition that the present invention is provided.
Another food that the present invention is provided, is active component with the composition that the present invention is provided.
Another health products that the present invention is provided, are active component with the composition that the present invention is provided.
The beneficial effect that technical solution of the present invention is realized：
The composition that the present invention is provided, it is mango leaf and stephania sinica is compatible so that having after both compatibilities improves blood
The pharmacological action of sugar and glycosylated hemoglobin, the DEVELOPMENT PROSPECT with medicine.
The composition that the present invention is provided, it is mango leaf and Radix Stephaniae Japonicae extract is compatible so that both have after compatibility
Improve the pharmacological action of blood sugar and glycosylated hemoglobin, the DEVELOPMENT PROSPECT with food, health products and medicine.
The composition that the present invention is provided, with mangiferin and rotundin as active component, also shows to improve blood sugar and saccharification
The pharmacological action of hemoglobin.
Specific embodiment
Technical scheme described in detail below.The embodiment of the present invention be merely illustrative of the technical solution of the present invention and
It is unrestricted, although being described in detail to the present invention with reference to preferred embodiment, it will be understood by those within the art that,
The technical scheme invented can be modified or equivalent, without deviating from the spirit and scope of technical solution of the present invention,
It all should cover in scope of the presently claimed invention.
If the reagent used by the present invention is not known indicating, it is purchased from Sigma-Aldrich (Sigma-
Aldrich)。
The mango leaf of embodiment 1 and stephania sinica are compatible
0.1~5 part of mixing of 0.3 part~7 parts of mango leaf and stephania sinica, test sample is obtained by way of powder processed or decocting
1。
The mango leaf of embodiment 2 and Radix Stephaniae Japonicae extract are produced
0.3 part~7 parts of mango leaf, 0.1~5 part of stephania sinica, plus 90% alcohol reflux are taken by weight extracts 2 times, the 1st
Secondary ethanol is 8 times of amounts, and 3 hours, the 2nd ethanol was 6 times of amounts, and 1 hour, double gauze filtration merged 2 filtrates, is recovered under reduced pressure
To without alcohol taste, relative density is 1.30 to ethanol when continuing to be concentrated under reduced pressure into 55 DEG C, obtains extract, is designated as test sample 2.
Embodiment 3 mangiferin is produced
With reference to《Chinese patent drug》The 1st phase content of page 161 of volume 34 in 2012, produces mangiferin monomeric compound, goes forward side by side
Row Structural Identification, data are as follows：
ESIMS(m/z)421[M-H]-。
1H-NMR (400MHz, Pyridine-d5) δ 14.62 (s, 1H), 8.11 (s, 1H), 7.18 (s, 1H), 6.64 (s,
1H), 5.88 (d, J=10.0Hz, 1H), 5.28-5.23 (m, 1H), 4.60 (d, J=10.4Hz, 1H), 4.53-4.44 (m,
3H), 4.25-4.23 (m, 1H).
13C-NMR (100MHz, Pyridine-d5) δ 182.4,167.3,165.2,159.6,158.1,154.1,147.5,
115.2,111.3,110.9,105.4,104.8,96.3,85.0,82.7,77.6,74.8,74.0,64.9.
The compound commodity can also be obtained, such as：Wuhan Hong Xinkang fine chemistry industries company.
Embodiment 4 rotundin is produced
With reference to《Guangxi Chemical Industry》The 2nd phase content of page 4 of volume 25 in 1996, produces rotundin monomeric compound, goes forward side by side
Row Structural Identification, data are as follows：
HR-MS, m/z：356.1856[M+H]+。
1H-NMR (600MHz, CD3OD), δ：6.91 (d, 1H, J=8.4Hz), 6.87 (d, 1H, J=8.4Hz), 6.84 (s,
1H), 6.69 (s, 1H), 4.17 (d, 1H, J=15.6Hz), 3.81 (s, 9H), 3.78 (s, 3H), 3.48 (d, 1H, J=
11.4Hz), 3.46 (d, 1H, J=15.6Hz), 3.40 (dd, 1H, J=16.2,3.6Hz), 3.17 (dd, 1H, J=11.4,
3.6Hz), 3.07 (td, 1H, J=16.2), 2.66~3.04 (m, 2H), 2.59 (td, 1H, J=11.4,3.6Hz).
13C-NMR (150MHz, CD3OD)δ：151.7,149.2,149.1,146.2,130.6,128.9,128.6,
127.8,125.2,112.9,112.6,110.4,60.8,60.5,56.7,56.4,56.3,54.8,52.7,36.5,29.3.
The compound commodity can also be obtained, such as：Wuhan Xing Zhongcheng Science and Technology Ltd.s.
Embodiment 5 with mangiferin and rotundin be active component compatibility
By weight, by mangiferin that is obtained or buying and rotundin consumption：Mangiferin 10%~90%, rotundin 10%
~90% compatibility, is obtained 2 groups of compositions, is designated as test sample 3 and test sample 4.
Influence of the embodiment 6 to Spontaneous Diabetic GK rat blood sugars
35 GK male rats of glucostasis value ＞ 9.0mmol/L are taken, 5 groups, respectively every group 7, mould are randomly divided into
The pharmaceutical composition group of the present invention of type control group, 1~test sample of test sample 4, separately with 7 with week old Wistar rats as normal right
According to group.Gastric infusion.
Using the steady person of outstanding talent's type blood glucose meter of Johnson ＆ Johnson, tail measuring blood sugar of blood extracting is cut.Determined during the random blood sugar morning 9~10；Fasting blood
Sugar (is determined) during the morning 9 for the hours blood glucose of fasting 6 during fasting afternoon 3.
Tail is cut before off-test and takes blood, glycosylated hemoglobin (HbA1c) is determined using Bio-Rad companies HbA1c analyzers.
Result is referring to table 1, table 2 and table 3.
Influence of the present composition of table 1 to GK rat fasting blood-glucoses
In table 1, * p ＜ 0.05, * * p ＜ 0.01 compares with model control group.
Table 1 is visible, and each test sample of each composition of the invention is respectively provided with reduction GK rat fasting blood-glucoses (p ＜ 0.05, p ＜
0.01), and effect is significant, the drug effect of monomeric compound combination is combined better than medicinal material.
Influence of the present composition of table 2 to GK rat random blood sugars
In table 2, * p ＜ 0.05, * * p ＜ 0.01 compares with model control group.
Table 2 is visible, and each test sample of each composition of the invention can significantly reduce GK rats random blood sugar (p ＜ 0.05, p
＜ 0.01), and effect is significant, the drug effect of monomeric compound combination is better than medicinal material combination.
Influence of the present composition of table 3 to GK rats glycosylated hemoglobin (HbA1c)
In table 3, * p ＜ 0.05, * * p ＜ 0.01 compares with model control group.
Table 3 is visible, and compared with model group, glycosylated hemoglobin (HbA1c) declines after each composition of the invention is administered 4 weeks
Significantly (p ＜ 0.05, p ＜ 0.01), the long term hyperglycemia state for pointing out each composition of the invention effectively to reduce GK rats.
Claims (9)
1. a kind of composition, it is characterised in that with mangiferin and its pharmaceutically acceptable salt and rotundin and its can pharmaceutically connect
The salt received is active component, and the compatibility relationship of two kinds of compositions by weight is：Mangiferin and its pharmaceutically acceptable salt 10%~
90%, rotundin and its pharmaceutically acceptable salt 10%~90%.
2. a kind of composition, it is characterised in that with mangiferin and its pharmaceutically acceptable salt and rotundin and its can pharmaceutically connect
The salt received is active component, and the compatibility relationship of two kinds of compositions by weight is：Mangiferin and its pharmaceutically acceptable salt 51%~
90%, rotundin and its pharmaceutically acceptable salt 10%~49%.
3. a kind of composition, it is characterised in that with mangiferin and its pharmaceutically acceptable salt and rotundin and its can pharmaceutically connect
The salt received is active component, and the compatibility relationship of two kinds of compositions by weight is：Mangiferin 61%~90%, rotundin 10%~
39%.
4. composition according to claims 1 to 3 is in the medicine of prevention and treatment diabetes, food or health products are prepared
Application.
5. composition according to claims 1 to 3 is in the medicine for improving glycosylated hemoglobin, food or health products are prepared
Application.
6. a kind of composition for preventing and treating diabetes, with the described composition of one of claims 1 to 3 as activity into
Point.
7. the composition for preventing and treating diabetes according to claim 6, it is characterised in that described composition
It is medicine.
8. the composition for preventing and treating diabetes according to claim 6, it is characterised in that described composition
It is food.
9. the composition for preventing and treating diabetes according to claim 6, it is characterised in that described composition
It is health products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611174510.6A CN106727964A (en) | 2016-12-16 | 2016-12-16 | Composition of dibenzopyrans ketone and morphinane alkaloid and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611174510.6A CN106727964A (en) | 2016-12-16 | 2016-12-16 | Composition of dibenzopyrans ketone and morphinane alkaloid and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727964A true CN106727964A (en) | 2017-05-31 |
Family
ID=58891352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611174510.6A Pending CN106727964A (en) | 2016-12-16 | 2016-12-16 | Composition of dibenzopyrans ketone and morphinane alkaloid and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727964A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008061480A1 (en) * | 2006-11-24 | 2008-05-29 | Hainan Deze Drug Research Co., Ltd | Novel mangiferin calcium salts, the method for its preparation and its use |
| CN101327214A (en) * | 2008-07-18 | 2008-12-24 | 中国药科大学 | Medicine use of isoquinoline alkaloids as tissue factor inhibitor |
| CN103169743A (en) * | 2013-04-24 | 2013-06-26 | 天津中医药大学 | Mango leaf extractive as well as preparation method and application thereof |
| CN103768112A (en) * | 2012-10-26 | 2014-05-07 | 昆明制药集团股份有限公司 | Mango leaf extract and application thereof |
-
2016
- 2016-12-16 CN CN201611174510.6A patent/CN106727964A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008061480A1 (en) * | 2006-11-24 | 2008-05-29 | Hainan Deze Drug Research Co., Ltd | Novel mangiferin calcium salts, the method for its preparation and its use |
| CN101327214A (en) * | 2008-07-18 | 2008-12-24 | 中国药科大学 | Medicine use of isoquinoline alkaloids as tissue factor inhibitor |
| CN103768112A (en) * | 2012-10-26 | 2014-05-07 | 昆明制药集团股份有限公司 | Mango leaf extract and application thereof |
| CN103169743A (en) * | 2013-04-24 | 2013-06-26 | 天津中医药大学 | Mango leaf extractive as well as preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 曹春林 等: "《中药制剂注解》", 28 February 1993, 上海科学技术出版社 * |
| 林华 等: "芒果苷对糖尿病小鼠糖脂代谢的影响", 《中药药理与临床》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN105753935A (en) | Small-molecule peptides of sunflower head as well as preparation method and medical application of small-molecule peptide | |
| CN102631526A (en) | Chinese medicinal composition for treating diabetes mellitus | |
| CN100423754C (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| KR100979459B1 (en) | Tetracera scandens extracts and 4H-chromen-4-one derivatives isolated therefrom increasing glucose uptake in differentiated L6 muscle cells | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN105434802A (en) | Pharmaceutical composition for treating diabetes, and preparation method and application thereof | |
| CN101455778B (en) | Traditional Chinese medicine preparation capable of reducing fever and relieving sore-throat and preparation method thereof | |
| CN104784192B (en) | The application of freshwater mussel meat oligosaccharides in hypoglycemic drug is prepared and preparation method thereof | |
| CN106727964A (en) | Composition of dibenzopyrans ketone and morphinane alkaloid and application thereof | |
| CN102552378A (en) | Lucerne and application of lucerne extract in preparing medicament for treating diabetes | |
| CN101229329A (en) | Indigestion tablet and preparing process thereof | |
| CN106491717A (en) | For preventing and treating the composition of diabetes | |
| CN110384709A (en) | Composition and its application containing phloridzin and 1-DNJ | |
| CN101249129B (en) | Chinese medicine extract combination and medicine use thereof | |
| CN106491718A (en) | Produce compositionss from two kinds of plant amedica and application thereof | |
| CN102048132B (en) | Health-care food for reducing blood sugar | |
| CN101406576B (en) | Chinese medicine for treating diabetes and preparation method | |
| CN101804083A (en) | Application of pollen pini and extract thereof in treating inflammatory bowel disease and method for preparing extract | |
| CN106581161A (en) | Composition for treatment and prevention of abnormal glucose metabolism and use thereof | |
| CN106474194A (en) | Combination of two kinds of plant amedica and application thereof | |
| CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
| CN104352748A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN106580977A (en) | Flavone and alkaloid composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170531 |